Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Composition",
"id" : "236951",
"meta" : {
"versionId" : "77",
"lastUpdated" : "2024-10-31T21:16:09.520Z",
"profile" : [
🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"url" : "https://fevir.net/resources/Composition/236951",
"identifier" : [
{
"type" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
"code" : "ACSN",
"display" : "Accession ID"
}
],
"text" : "FEvIR Object Identifier"
},
"system" : "urn:ietf:rfc:3986",
"value" : "https://fevir.net/FOI/236951",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
{
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "SummaryOfFindings",
"display" : "SummaryOfFindings"
}
],
"text" : "Summary of Findings"
},
"date" : "2024-10-31T21:16:09.520Z",
"author" : [
{
"type" : "Practitioner",
"display" : "Qiukui Hao"
}
],
"title" : "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes",
"custodian" : {
🔗 "reference" : "Organization/118079",
"type" : "Organization",
"display" : "Computable Publishing LLC"
},
"relatesTo" : [
{
"type" : "part-of",
"resourceReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-conversion-report",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
}
},
{
"type" : "part-of",
"label" : "Part of",
"resourceReference" : {
"type" : "Composition",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "ComparativeEvidenceReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
},
{
"type" : "cite-as",
"label" : "Cite as",
"citation" : "SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2024-10-31. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/FLI/DocumentForComposition236951."
}
],
"section" : [
{
"title" : "Column Headers",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "column-headers",
"display" : "Column Headers"
}
]
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Outcome</div>"
}
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Sample size: # studies, # participants, # counted, # events</div>"
}
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Result Without Treatment</div>"
}
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Result With Treatment (Observed)</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Result With Treatment (Calculated)</div>"
}
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Effect Estimate (Relative effect)</div>"
}
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">Certainty of finding (Quality of evidence)</div>"
}
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">What this means</div>"
}
}
]
},
{
"title" : "Summary of Findings",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings",
"display" : "Summary of Findings"
}
]
},
"section" : [
{
"title" : "All-cause mortality",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236953",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313956",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: All-cause mortality"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All-cause mortality</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236953",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313956",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: All-cause mortality"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">2 studies, 1282 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">24.1%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236955",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">21.8%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236955",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference -2.3% ( -4% to -0.4%); Odds Ratio 0.88 ( 0.79 to 0.98)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236954",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Cardiovascular mortality",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236956",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313957",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Cardiovascular mortality"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Cardiovascular mortality</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236956",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313957",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Cardiovascular mortality"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1 studies, 463 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">15.7%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236958",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">15.2%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236958",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference -0.5% ( -2.2% to 1.2%); Odds Ratio 0.96 ( 0.84 to 1.09)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236957",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Nonfatal myocardial infarction",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal myocardial infarction"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Nonfatal myocardial infarction</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236959",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313958",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal myocardial infarction"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1 studies, 463 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236960",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">17.7%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236961",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">17%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236961",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236960",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference -0.7% ( -2.4% to 1.1%); Odds Ratio 0.95 ( 0.84 to 1.08)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236960",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236960",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236960",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Nonfatal stroke",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236962",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313959",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal stroke"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Nonfatal stroke</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236962",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313959",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Nonfatal stroke"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">2 studies, 1282 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236963",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">16.5%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236964",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">19.2%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236964",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236963",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference 2.7% ( 0.4% to 5.3%); Odds Ratio 1.2 ( 1.03 to 1.41)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236963",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236963",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"> SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236963",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "End-stage kidney disease",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236965",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: End-stage kidney disease"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">End-stage kidney disease</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236965",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313960",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: End-stage kidney disease"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1 studies, 463 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236966",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">11.9%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236967",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">10.9%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236967",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236966",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference -1% ( -3.4% to 2%); Odds Ratio 0.91 ( 0.69 to 1.2)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236966",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236966",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236966",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Heart failure",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236968",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313961",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Heart failure"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Heart failure</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236968",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313961",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Heart failure"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No sample size data found.]</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236969",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">22.4%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236970",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">17.6%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236970",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236969",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference -4.8% ( -6.6% to -2.7%); Odds Ratio 0.74 ( 0.65 to 0.85)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236969",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">High certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236969",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236969",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Diabetic ketoacidosis",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236971",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313962",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Diabetic ketoacidosis"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Diabetic ketoacidosis</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236971",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313962",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Diabetic ketoacidosis"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1 studies, 463 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236972",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">0.1%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236973",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">0.2%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236973",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236972",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference 0.1% ( 0% to 0.3%); Odds Ratio 1.71 ( 0.79 to 3.69)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236972",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">High certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236972",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236972",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Serious hyperglycaemia",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Serious hyperglycaemia"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Serious hyperglycaemia</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236974",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313963",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Serious hyperglycaemia"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1 studies, 463 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236975",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236976",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">1.5%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236976",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236975",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference 0.5% ( -0.2% to 1.9%); Odds Ratio 1.48 ( 0.75 to 2.93)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236975",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">High certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236975",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236975",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Genital infection",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236977",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313964",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Genital infection"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Genital infection</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236977",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313964",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Genital infection"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">2 studies, 1282 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236978",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">5%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236979",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">20.8%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236979",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236978",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference 15.8% ( 6.4% to 29.9%); Odds Ratio 5 ( 2.45 to 10.2)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236978",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">High certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236978",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236978",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Severe gastrointestinal events",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236980",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313965",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Severe gastrointestinal events"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Severe gastrointestinal events</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236980",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-313965",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Severe gastrointestinal events"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">7 studies, 24638 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236981",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">4.4%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236982",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">10.2%</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236982",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236981",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Risk Difference 5.8% ( 0.9% to 14.2%); Odds Ratio 2.46 ( 1.22 to 4.97)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236981",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Very low certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236981",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236981",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Health-related quality of life",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Health-related quality of life"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Health-related quality of life</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236983",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109587",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Health-related quality of life"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[No sample size data found.]</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Not a proportion.]"
},
"entry" : [
{
🔗 "reference" : "Evidence/236985",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[Not a proportion.]</div></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236985",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Standardized Mean Difference 0.01 ( -0.19 to 0.2)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Low certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236984",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
},
{
"title" : "Body weight",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "summary-of-findings-entry-for-a-single-outcome",
"display" : "Summary of findings entry for a single outcome"
}
]
},
"focus" : {
🔗 "reference" : "EvidenceVariable/236986",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109588",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Body weight"
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
},
"section" : [
{
"title" : "Outcome",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "outcome-measure",
"display" : "Outcome Measure"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Body weight</div>"
},
"entry" : [
{
🔗 "reference" : "EvidenceVariable/236986",
"type" : "EvidenceVariable",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-109588",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "OutcomeDefinition: Body weight"
}
]
},
{
"title" : "Sample Size",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "sample-size",
"display" : "Sample Size"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">2 studies, 1139 participants</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Result Without Treatment",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-comparator-alone",
"display" : "Result with comparator alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">[Not a proportion.]"
},
"entry" : [
{
🔗 "reference" : "Evidence/236988",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight Comparator Evidence"
}
]
},
{
"title" : "Result With Treatment--Observed",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone",
"display" : "Result with intervention alone"
}
]
},
"text" : {
"status" : "empty",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[No data]</div>"
}
},
{
"title" : "Result With Treatment--Derived",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-alone-calculated",
"display" : "Result with intervention alone (calculated)"
}
],
"text" : "result with intervention with calculated value derived from the control group and effect estimate"
},
"text" : {
"status" : "generated",
"div" : "<div xmlns =\"http://www.w3.org/1999/xhtml\">[Not a proportion.]</div></div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236988",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-only-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight Comparator Evidence"
},
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Effect Estimate",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "result-with-intervention-vs-comparator",
"display" : "Result with intervention vs. comparator"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Mean Difference -0.47 Kg ( -0.09 Kg to -0.85 Kg)</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Certainty of Evidence",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "certainty-of-evidence",
"display" : "Certainty of Evidence"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">Moderate certainty</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
},
{
"title" : "Assertion",
"code" : {
"coding" : [
{
"system" : "https://fevir.net/resources/CodeSystem/179423",
"code" : "assertion",
"display" : "Assertion"
}
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</div>"
},
"entry" : [
{
🔗 "reference" : "Evidence/236987",
"type" : "Evidence",
"identifier" : {
"type" : {
"text" : "FEvIR Linking Identifier"
},
"system" : "https://fevir.net/FLI",
"value" : "MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence",
"assigner" : {
"display" : "Computable Publishing LLC"
}
},
"display" : "MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"
}
]
}
]
}
]
}
]
}
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-11-21
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change